Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Target Price
The average target price of NAUT is 2.5 and suggests 12% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
Buy
Sell